

Rajesh Pahwa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10064518/publications.pdf>

Version: 2024-02-01

125
papers

9,327
citations

53751

45
h-index

39638

94
g-index

127
all docs

127
docs citations

127
times ranked

6331
citing authors

#	ARTICLE	IF	CITATIONS
1	Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease_{A Randomized Controlled Trial}. JAMA - Journal of the American Medical Association, 2009, 301, 63.	3.8	1,253
2	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. Movement Disorders, 2006, 21, S290-S304.	2.2	811
3	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Annals of Neurology, 1997, 42, 292-299.	2.8	508
4	Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurology, The, 2012, 11, 140-149.	4.9	354
5	Long-term evaluation of deep brain stimulation of the thalamus. Journal of Neurosurgery, 2006, 104, 506-512.	0.9	325
6	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
7	Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. Movement Disorders, 2001, 16, 464-468.	2.2	266
8	Deep brain stimulation: Preoperative issues. Movement Disorders, 2006, 21, S171-S196.	2.2	260
9	Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology, 2007, 68, 1262-1267.	1.5	256
10	Pharmacotherapy of Essential Tremor. CNS Drugs, 2008, 22, 1037-1045.	2.7	226
11	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 216.	4.5	171
12	National randomized controlled trial of virtual house calls for Parkinson disease. Neurology, 2017, 89, 1152-1161.	1.5	169
13	Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. Movement Disorders, 2001, 16, 140-143.	2.2	163
14	Quality of life in Essential Tremor Questionnaire (QUEST): Development and initial validation. Parkinsonism and Related Disorders, 2005, 11, 367-373.	1.1	157
15	Interactive video conferencing: A means of providing interim care to parkinson's disease patients. Movement Disorders, 1993, 8, 380-382.	2.2	141
16	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study). JAMA Neurology, 2017, 74, 941.	4.5	137
17	Efficacy of unilateral deep brain stimulation of the vim nucleus of the thalamus for essential head tremor. Movement Disorders, 1999, 14, 847-850.	2.2	134
18	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Movement Disorders, 2017, 32, 1701-1709.	2.2	134

#	ARTICLE	IF	CITATIONS
19	Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). <i>Movement Disorders</i> , 2015, 30, 788-795.	2.2	123
20	Deep Brain Stimulation and Tremor. <i>Neurotherapeutics</i> , 2008, 5, 331-338.	2.1	122
21	Double-blind controlled trial of gabapentin in essential tremor. <i>Movement Disorders</i> , 1998, 13, 465-467.	2.2	120
22	Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. <i>Journal of Neurosurgery</i> , 2003, 99, 71-77.	0.9	120
23	Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience. <i>Movement Disorders</i> , 1998, 13, 377-382.	2.2	105
24	Essential tremor: differential diagnosis and current therapy. <i>American Journal of Medicine</i> , 2003, 115, 134-142.	0.6	102
25	Benefits and Risks of Pharmacological Treatments for Essential Tremor. <i>Drug Safety</i> , 2003, 26, 461-481.	1.4	94
26	Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. <i>Lancet Neurology</i> , The, 2020, 19, 491-501.	4.9	88
27	Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. <i>Journal of Neurosurgery</i> , 2006, 104, 502-505.	0.9	84
28	Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 145-154.	4.9	82
29	Effects of thalamic deep brain stimulation based on tremor type and diagnosis. <i>Movement Disorders</i> , 1997, 12, 337-341.	2.2	80
30	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	4.9	80
31	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	3.8	80
32	Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. <i>Journal of the Neurological Sciences</i> , 2007, 258, 137-143.	0.3	76
33	Levodopa-related wearing-off in Parkinson's disease: identification and management. <i>Current Medical Research and Opinion</i> , 2009, 25, 841-849.	0.9	76
34	Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 142-148.	1.1	76
35	Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1997, 20, 523-530.	0.2	71
36	Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. <i>Journal of Neurosurgery</i> , 2005, 103, 252-255.	0.9	70

#	ARTICLE	IF	CITATIONS
37	Preoperative Clinical Predictors of Response to Bilateral Subthalamic Stimulation in Patients with Parkinson's Disease. <i>Stereotactic and Functional Neurosurgery</i> , 2005, 83, 80-83.	0.8	68
38	Classification of Parkinson's disease and essential tremor based on balance and gait characteristics from wearable motion sensors via machine learning techniques: a data-driven approach. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020, 17, 125.	2.4	68
39	Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 461-464.	0.6	62
40	Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor. <i>Journal of Neurosurgery</i> , 2012, 117, 156-161.	0.9	59
41	Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 18-26.	1.1	59
42	Improvements in daily functioning after deep brain stimulation of the thalamus for intractable tremor. <i>Movement Disorders</i> , 1998, 13, 690-692.	2.2	55
43	Transdermal dopaminergic D2receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2001, 16, 459-463.	2.2	54
44	Analysis of Pallidotomy Lesion Positions Using Three-dimensional Reconstruction of Pallidal Lesions, the Basal Ganglia, and the Optic Tract. <i>Neurosurgery</i> , 1997, 41, 1303-1318.	0.6	52
45	An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. <i>Neuromodulation</i> , 2019, 22, 537-545.	0.4	52
46	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. <i>Telemedicine Journal and E-Health</i> , 2016, 22, 590-598.	1.6	47
47	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 898.e1-898.e7.	1.2	46
48	Brain activity during dual task gait and balance in aging and age-related neurodegenerative conditions: A systematic review. <i>Experimental Gerontology</i> , 2019, 128, 110756.	1.2	43
49	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. <i>Journal of Parkinson's Disease</i> , 2017, 7, 511-522.	1.5	42
50	Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 669-680.	1.4	42
51	Dyskinesia Matters. <i>Movement Disorders</i> , 2020, 35, 392-396.	2.2	42
52	Thalamic stimulation for midbrain tremor after partial hemangioma resection. <i>Movement Disorders</i> , 2002, 17, 404-407.	2.2	41
53	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on "Off"-time in Patients with Advanced Parkinson's Disease: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 2854-2890.	1.3	41
54	Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 63-71.	1.1	39

#	ARTICLE	IF	CITATIONS
55	Deep brain stimulation for essential tremor. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 155-166.	1.0	37
56	Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism and Related Disorders, 2019, 60, 126-132.	1.1	37
57	Long-Term Efficacy of Globus pallidus Stimulation for the Treatment of Parkinson's Disease. Stereotactic and Functional Neurosurgery, 2002, 79, 214-220.	0.8	35
58	Pharmacokinetics of ADS-5102 (Amantadine) Extended-Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clinical Pharmacokinetics, 2019, 58, 77-88.	1.6	35
59	Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor and Other Hyperkinetic Movements, 2020, 10, 29.	1.1	35
60	Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia. Journal of the Neurological Sciences, 2012, 319, 24-31.	0.3	34
61	Diabetes mellitus presenting as paroxysmal kinesigenic dystonic choreoathetosis. Movement Disorders, 1995, 10, 353-355.	2.2	33
62	Treatment of early Parkinson's disease. Current Opinion in Neurology, 2014, 27, 442-449.	1.8	33
63	Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor. Sensors, 2019, 19, 5153.	2.1	33
64	Deep brain stimulation in Parkinson's disease. Current Neurology and Neuroscience Reports, 2004, 4, 290-295.	2.0	31
65	Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study. Movement Disorders, 2003, 18, 584-587.	2.2	30
66	Paradoxical Effect of Dopamine Medication on Cognition in Parkinson's Disease: Relationship to Side of Motor Onset. Journal of the International Neuropsychological Society, 2015, 21, 259-270.	1.2	29
67	Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in parkinson's disease: Pharmacokinetic and quality-of-life measures. Movement Disorders, 1997, 12, 677-681.	2.2	28
68	Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of "off" episodes in patients with Parkinson's disease. Current Medical Research and Opinion, 2007, 23, 741-750.	0.9	27
69	Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease. Therapeutics and Clinical Risk Management, 2018, Volume 14, 665-673.	0.9	27
70	Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 155-161.	0.7	26
71	Postural tremor suppression is dependent on thalamic stimulation frequency. Movement Disorders, 2006, 21, 1290-1292.	2.2	25
72	Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Advances in Therapy, 2019, 36, 2233-2246.	1.3	25

#	ARTICLE	IF	CITATIONS
73	Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. American Journal of Managed Care, 2010, 16 Suppl Implications, S94-9.	0.8	25
74	Cognitive impairment in Parkinson's disease. European Journal of Neurology, 1998, 5, 431-441.	1.7	24
75	Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease. Journal of the Neurological Sciences, 2017, 383, 42-46.	0.3	23
76	Clinical utility of DaTscanâ„¢ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Review of Neurotherapeutics, 2017, 17, 219-225.	1.4	22
77	Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. Parkinsonism and Related Disorders, 2019, 60, 118-125.	1.1	21
78	Ropinirole therapy for Parkinson's disease. Expert Review of Neurotherapeutics, 2004, 4, 581-588.	1.4	20
79	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 543-558.	1.5	20
80	A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of ^{CX}â„¢8998 in Essential Tremor. Movement Disorders, 2021, 36, 1944-1949.	2.2	18
81	Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraphâ„¢. Journal of Clinical Movement Disorders, 2020, 7, 5.	2.2	17
82	Amantadine ER (Gocovriâ„¢) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 645706.	1.1	17
83	The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. Neurodegenerative Disease Management, 2018, 8, 73-80.	1.2	16
84	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-Label ADSâ„¢5102. Movement Disorders Clinical Practice, 2018, 5, 183-190.	0.8	15
85	Old Drugs, New Delivery Systems in Parkinson's Disease. Drugs and Aging, 2019, 36, 807-821.	1.3	15
86	Presurgical Coping, Depression, and Quality of Life in Persons with Parkinson's Disease. Journal of Clinical Psychology in Medical Settings, 2003, 10, 101-107.	0.8	14
87	ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. JAMA Neurology, 2017, 74, 1507.	4.5	12
88	Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75 years of age. Journal of the Neurological Sciences, 2019, 399, 57-60.	0.3	12
89	Subthalamic Nucleus Stimulation in Parkinson's Disease Patients Intolerant to Levodopa. Stereotactic and Functional Neurosurgery, 2007, 85, 169-174.	0.8	11
90	Pupillary Response to Cognitive Demand in Parkinson's Disease: A Pilot Study. Frontiers in Aging Neuroscience, 2018, 10, 90.	1.7	10

#	ARTICLE	IF	CITATIONS
91	Does post-operative symptomatic lead edema associated with subthalamic DBS implantation impact long-term clinical outcomes?. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116647.	0.3	10
92	Reliability and Validity of Pupillary Response During Dual-Task Balance in Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 448-455.	0.5	9
93	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021, 10, 307-320.	1.4	9
94	Stimulation of the motor cortex for disabling essential tremor. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 564-567.	0.6	8
95	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , 2018, 23, 402-413.	0.7	8
96	Extended-Release Amantadine for Levodopa-Induced Dyskinesia. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 293-299.	1.4	8
97	Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. <i>Neurologic Clinics</i> , 2004, 22, S35-S52.	0.8	7
98	Amantadine: an old drug reborn. <i>Lancet Neurology</i> , The, 2021, 20, 975-977.	4.9	7
99	Outpatient titration of carbidopa/levodopa enteral suspension (Duopa). <i>International Journal of Neuroscience</i> , 2017, 127, 459-465.	0.8	6
100	Pupillary Response to Postural Demand in Parkinson's Disease. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 617028.	2.0	6
101	<scp>THN</scp> 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. <i>Movement Disorders</i> , 2022, 37, 410-415.	2.2	6
102	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries. <i>Neurology and Therapy</i> , 2022, 11, 303-318.	1.4	6
103	Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 681-691.	1.3	5
104	Effect of Behavioral Intervention on Comorbid General Anxiety Disorder and Parkinson's Disease. <i>Clinical Gerontologist</i> , 2008, 32, 104-117.	1.2	4
105	Deep brain stimulation for Parkinson's disease: current status and future outlook. <i>Neurodegenerative Disease Management</i> , 2016, 6, 299-317.	1.2	4
106	Cognitive workload during verbal abstract reasoning in Parkinson's disease: a pilot study. <i>International Journal of Neuroscience</i> , 2021, 131, 504-510.	0.8	3
107	Exploring essential tremor: Results from a large online survey. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 5, 100101.	0.5	2
108	Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 52-57.	1.1	2

#	ARTICLE	IF	CITATIONS
109	Thalamic Deep Brain Stimulation for Parkinson's Disease Tremor. , 2008, , 229-241.		2
110	Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease. Journal of Clinical Psychiatry, 2020, 81, .	1.1	2
111	Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson's Disease. Touch Reviews in Neurology, 2021, 17, 36.	0.1	1
112	Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses. Neurology and Therapy, 2022, , .	1.4	1
113	Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. International Journal of Psychiatry in Clinical Practice, 2023, 27, 69-81.	1.2	1
114	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study). Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	0
115	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD-Adjunct Study). , 0, , 73-84.		0
116	Managing essential tremor patients treated with deep brain stimulation. , 0, , 56-61.		0
117	Managing essential tremor patients treated with deep brain stimulation. , 0, , 77-83.		0
118	The characterization of a base-width neutral step as the first step for balance recovery in moderate Parkinson's disease. International Journal of Neuroscience, 2016, 126, 713-722.	0.8	0
119	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. Movement Disorders, 2020, 35, 901-901.	2.2	0
120	Thalamic Deep Brain Stimulation and Essential Tremor. , 2008, , 205-214.		0
121	A stimulating treatment for essential tremor. , 2008, , 321-323.		0
122	Deep brain stimulation. , 2013, , 478-495.		0
123	Beneficial Effects of Green Tea Consumption in Parkinson's Disease Patients. FASEB Journal, 2013, 27, 368.1.	0.2	0
124	Tremor: Phenomenology, Etiology, Diagnosis, and Treatment. , 2017, , 303-314.		0
125	Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic. Telemedicine Journal and E-Health, 2022, , .	1.6	0